SynteractHCR selected for Phase III trial of diabetic nasal spray

SynteractHCR selected for Phase III trial of diabetic nasal spray
SynteractHCR selected for Phase III trial of diabetic nasal spray

Related tags The canon of medicine

Evoke Pharma has selected SynteractHCR to carry out Phase III trials of its nasal spray drug EVK-001.

The drug - a metoclopramide nasal spray - is intended to relieve symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus and recently completed a Phase IIb trial, also carried out by SynteractHCR.

Evoke’s CEO, Dave Gonyer, said: “As we prepare to commence this important initiative, we believe the selection of the same CRO and the planned inclusion of many of the same Phase IIb study sites will maximize the use of our knowledge base to expedite initiation and completion of Phase III.”

The Phase 3 enrollment target is 200 completed patients and enrollment is expected to begin in the first half of 2014.

Synteract and HCR merged earlier this year​, creating a combined workforce of over 800 operating in 16 different countries.

Related topics Clinical Development Phase III-IV

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers